Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
ConditionSystemic Lupus Erythematosus
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
The study aims at defining the role of ferroptosis s in the physiopathology of systemic lupus erythematosus (SLE). Ferroptosis (phenomenon of cellular death regulated by iron) is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.
Eligibility criteria
Qualifiers
age ≥ 18 years;
diagnosis of systemic lupus erythematosus;
being affiliated to health insurance, willing to participate and to sign informed consent;
control group : patients with a diagnosis of rheumatoid arthritis or an inflammatory bowel disease.
Disqualifiers
pregnant or breastfeeding women;
patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Trial design
Treatments tested in this trial
- blood sample
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov